Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200020/S011

ClearView 3 IOL

Lenstec, Inc. · Decision date Mar 25, 2026

FDA DECISIONP200020/S011

What did the FDA approve?

FDA records P200020/S011 as a supplement to PMA P200020, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Mar 25, 2026.

FDA approval order statement

approval for an extension of the power range from +15.0 through +30.0D to +10.0 through +36.0D for the ClearView 3 intraocular lenses (IOLs)
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Ophthalmic
Decision date
Mar 25, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P200020/S011
Regulatory pathway
PMA supplement
Applicant
Lenstec, Inc.
Product code
MFK
Decision code
APPR
Decision date
Mar 25, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lens, multifocal intraocular.

Applicant
Lenstec, Inc.
Product code
MFK
FDA device class
3

For the original device and its historical approval scope, see PMA P200020. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200020 · Original PMA

    SBL-3 Multifocal Intraocular Lens

  2. P200020/S011 received

    Application receipt date recorded by FDA.

  3. P200020/S011 · FDA decision

    Real-Time Process

  4. P200020/S013 · Related supplement

    ClearView HD intraocular lens (IOL)

Timeline entries are records held by MedtechLedger for P200020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200020

Product / regulatory recordCompanyPathwayDecision dateSource
Lenstec, Inc.PMA approvalJul 22, 2022FDA
ClearView 3 LensP200020/S009
Lenstec, Inc.PMA supplementAug 12, 2025FDA
ClearView 3P200020/S010
Lenstec, Inc.PMA supplementDec 4, 2025FDA
Clearview 3P200020/S012
Lenstec, Inc.PMA supplementApr 15, 2026FDA
Lenstec, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Other records with product code MFK

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Lenstec, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1765 Commerce Ave. N, St. Petersburg, FL, 33716

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records